

Table S1 Patient characteristics, intraoperative and postoperative findings of COVID-19-associated ARDS lung transplant recipients with VV-ECMO bridge

Patient No.	Age decade	BMI, kg/m ²	Sex	Pre VV ECMO days	OR time (hours)	Ischemic time	VA ECMO time	IntraOp RBC	IntraOp FFP	IntraOp Plt	ICU stay	Ventilator days	Pleural drainage	Post Op ECMO days	Hospital stay, days	PGD grade	Require inotropes	Required inhaled nitric oxide
1	20s	33.6	F	35	8.3	5.3	2.5	6	2	3	21	17	14	17	33	3	No	No
2	60s	27.2	M	101	9.5	5.0	3.2	10	6	1	15	1	24	9	38	3	No	No
3	43s	20.7	M	87	10.8	5.1	2.8	16	8	4	4	20	23	8	37	3	No	No
4	60s	25.8	M	40	9.3	6.0	2.8	10	2	2	28	4	61	1	92	0	No	No
5	50s	24.5	M	52	9.2	5.3	2.8	5	0	0	33	18	20	5	58	3	No	No
6	40s	35.7	F	58	10.3	4.4	3.1	10	0	3	16	1	13	0	50	0	No	No
7	30s	30.2	F	66	10.0	6.0	4.8	14	4	2	41	17	31	0	47	2	No	No
8	60s	27.6	M	129	11.1	8.1	5.3	19	8	2	23	16	17	4	28	2	No	No
9	60s	26.8	M	80	9.6	5.6	3.1	5	1	0	25	4	29	4	29	1	No	No
10	30s	26.6	F	42	8.3	4.9	2.6	7	1	1	12	12	15	1	17	0	No	No
11	50s	21.7	M	68	9.8	7.0	4.5	18	11	8	20	3	20	0	36	0	No	No
12	30s	26.7	F	121	8.2	6.0	3.1	7	0	1	33	29	25	5	35	3	No	No
13	60s	28.6	M	113	11.0	6.3	4.0	17	6	3	12	9	21	1	22	1	No	No
14	50s	28.3	F	126	10.8	6.1	5.0	16	4	2	19	0	32	5	35	3	No	No
15	60s	21.5	F	158	9.1	6.5	3.3	17	12	5	18	18	18	4	18	3	No	No
16	30s	26.6	M	33	9.1	5.8	2.7	9	1	2	21	15	19	8	25	3	No	No
17	50s	29.0	M	62	7.5	5.2	2.1	7	5	3	31	4	4	0	38	2	No	No
18	50s	30.2	M	200	9.4	6.7	4.3	4	2	2	20	3	13	4	23	0	No	No
19	40s	22.0	M	81	10.0	6.0	Not applicable	27	22	6	40	10	12	6	76	3	No	No
20	60s	21.5	M	34	11.4	5.3	3.9	8	3	1	13	1	12	2	13	0	No	No
21	40s	30.2	F	7	9.7	6.0	3.6	10	11	3	15	2	15	3	21	0	No	No
22	50s	23.0	M	123	8.3	6.2	4.7	10	2	3	20	1	14	0	32	2	No	No
23	40s	21.2	F	270	11.5	7.1	4.2	29	19	12	119	119	30	8	60	3	No	No
24	50s	33.0	F	300	7.6	5.6	3.3	14	6	4	7	3	13	0	15	1	No	No
25	30s	27.3	F	214	7.1	7.6	4.3	18	13	4	38	35	38	15	38	3	No	No

COVID-19, coronavirus disease 2019; ARDS, acute respiratory distress syndrome; VV-ECMO, veno-venous extracorporeal membrane oxygenation.

Table S2 The number of deaths and etiologies among patients on the waiting list during the study period

	Total N=15
COVID-19-associated ARDS	8
With ECMO bridge	(6)
Without ECMO bridge	(2)
ILD	4
COPD	2
Bronchoalveolar-Carcinoma	1

COVID-19, coronavirus disease 2019; ARDS, acute respiratory distress syndrome; ECMO, extracorporeal membrane oxygenation; ILD, interstitial lung disease; COPD, chronic obstructive pulmonary disease.

Table S3 Wilcoxon signed-rank test for the echocardiogram results of pre and post LTx patients with VV-ECMO bridge

Variable	Pre LTx	Post LTx	Paired number	P value
PWs (cm)	1.0 (0.9–1.1)	1.0 (1.0–1.1)	24	0.23
LVIDd (cm)	4.4 (4.0–4.6)	4.2 (3.8–4.6)	24	0.72
LVIDs (cm)	2.7 (2.4–3.0)	2.6 (2.5–3.0)	24	0.52
IVS (cm)	1.1 (1.0–1.1)	1.0 (0.9–1.2)	24	0.36
LAVI	22.6 (16.8–29.1)	24.7 (17.7–42.4)	15	0.008
EF (bi-plane)	64.0 (59.0–70.5)	67.0 (61.0–70.0)	24	0.97
Mitral E (cm/s)	0.7 (0.5–0.9)	0.7 (0.6–0.9)	18	0.17
Mitral A (cm/s)	0.7 (0.7–0.8)	0.7 (0.5–0.8)	15	0.03
Average E/e'	9.5 (7.8–10.8)	8.2 (7.4–10.4)	17	0.95
Sep E' (cm/s)	6.9 (5.9–7.9)	7.2 (5.9–9.4)	18	0.49
Sep E/e'	11.8 (7.1–14.3)	9.7 (8.1–12.1)	17	0.64
Lat E' (cm/s)	9.4 (7.0–11.1)	10.1 (9.5–12.3)	17	0.06
RVSP	45.7 (30.8–50.1)	29.0 (25.5–32.0)	16	0.01
RV S'	10.2 (9.8–11.7)	10.7 (10.2–11.4)	13	0.53
TAPSE	19.6 (16.0–22.1)	15.3 (14.1–18.1)	18	0.02
RV GLS	-12.9 (-15.2 to -9.5)	-17.7 (-22.3 to -15.7)	9	0.06
RV wall thickness	0.6 (0.5–0.8)	0.6 (0.5–0.7)	7	0.06

Continuous data are shown as median and interquartile range (IQR) 1 to IQR 3. LTx, lung transplantation; VV-ECMO, veno-venous extracorporeal membrane oxygenation; PW, posterior wall; LVIDd, left ventricular internal dimensions in end-diastole; LVIDs, left ventricular internal dimensions in end-systole; IVS, intraventricular septum; LAVI, left atrial volume index; EF, ejection fraction; Sep, septum; Lat, lateral; RV, right ventricular; TAPSE, tricuspid annular plane systolic excursion; GLS, global longitudinal strain.